This clinical trial is focused on studying a condition known as Grade II acute graft-versus-host disease (GVHD), which can occur after a patient receives a stem cell transplant from a donor. This condition often affects the skin and may also involve the upper part of the digestive system. The study aims to compare two different treatment approaches for this condition. One group of patients will receive treatment with corticosteroids alone, while the other group will receive a combination of corticosteroids and a procedure called extracorporeal photopheresis (ECP). ECP is a process where blood is treated outside the body to help manage the disease.
The trial will involve the use of several medications. SOLUMEDROL, which contains the active ingredient methylprednisolone hemisuccinate, and CORTANCYL, which contains prednisone, are both corticosteroids used in the study. Additionally, Uvadex, containing methoxsalen, is used in conjunction with the ECP procedure. Another medication, Noxafil, which contains posaconazole, is also part of the study. The purpose of the study is to determine which treatment approach is more effective in preventing treatment failure, which means the disease does not worsen or require additional treatment, over a period of six months.
Participants in the study will be randomly assigned to one of the two treatment groups. The study will last for several months, during which patients will receive their assigned treatment and be monitored for any changes in their condition. The goal is to see how well each treatment works in managing the symptoms of acute GVHD and to assess the overall health and quality of life of the participants. The study will also track any side effects or complications that may arise during the treatment period.
France 
